• Conversations around breastfeeding and microdosing are often reduced to simplistic ideas of “safe” or “unsafe.” Yet for many mothers, the reality is far more complex.

    As interest in microdosing grows, increasing numbers of women are exploring these substances in the context of postpartum mental health, emotional wellbeing and nervous system regulation, despite very limited formal research around psilocybin and breastfeeding.

    This article is not intended as medical advice or encouragement to microdose while breastfeeding. Rather, it is an invitation into a more nuanced conversation around uncertainty, maternal wellbeing and informed decision making.

  • What Do We Currently Know?

    At present, there are no clinical studies specifically examining psilocybin microdosing and breastmilk transfer in humans, long term infant outcomes, or breastfeeding safety. Pregnant and breastfeeding women are routinely excluded from psychedelic studies, leaving many mothers navigating these questions without clear guidance.

  • Psilocybin is converted in the body into psilocin, the active compound responsible for its psychedelic effects. There is currently very little data showing exactly how much psilocin passes into breastmilk, how long it remains there, or what level of exposure a breastfeeding baby might receive.

    Some pharmacological perspectives suggest psilocin may be able to transfer into breastmilk because many psychoactive substances can cross biological barriers. Other perspectives suggest its binding to human serum albumin may reduce the likelihood of large amounts diffusing into breastmilk. However, these remain theoretical considerations rather than direct human studies.

    Microdosing adds another layer to the conversation. A microdose is, by definition, a very small amount compared with a full psychedelic dose. Some mothers therefore feel any amount passing into breastmilk may be negligible, while others prefer to minimise even tiny potential exposure.

    This leads to very different approaches.

    Some mothers choose to time microdosing around feeding, dosing immediately after a feed, leaving longer gaps before the next feed, or using stored milk. Others decide not to microdose while breastfeeding at all.

    There are also mothers who hold a different perspective entirely: that small amounts passing through breastmilk may not necessarily be harmful and could even be beneficial. This view is often rooted in more relational or traditional understandings of medicine, where the mother baby relationship is seen as deeply interconnected rather than separate.

    Projects such as Mothers of the Mushroom, a citizen led research initiative gathering stories from mothers exploring psilocybin during pregnancy, postpartum and breastfeeding have emerged partly in response to the absence of formal research.

    In the project’s initial survey of 411 mothers, 237 participants (57%) reported ingesting psilocybin while breastfeeding. Many described turning toward microdosing in the context of postpartum depletion, anxiety, emotional overwhelm, trauma, isolation or a desire to feel more emotionally present within motherhood itself.

    Some mothers reported feeling calmer, more emotionally regulated and more connected to both themselves and their babies.

    One participant shared that microdosing helped her feel:

    “more emotionally connected to my baby and more capable of navigating the challenges of early parenthood with calm and clarity.”

    Another described:

    “feeling my feelings and connect with myself and others and my baby.”

    At the same time, some mothers reported increased sensitivity, anxiety or uncertainty around infant exposure. Experiences are not universally positive, and there is no one size fits all approach.

  • What About Animal Studies?

    Animal studies exploring psilocybin exposure during pregnancy and postpartum periods are often cited within these discussions. However, applying these findings directly to human microdosing during breastfeeding is highly problematic.

    Many of these studies involve large doses, stressed laboratory animals and experimental conditions that bear little resemblance to carefully calibrated human microdosing in real world maternal contexts.

    While these studies may offer useful biological clues and highlight areas requiring further research, they cannot reliably predict the outcomes of low dose microdosing practices in breastfeeding mothers.

    This points to a wider challenge within psychedelic research itself: context matters. Set, setting, stress, relational support and environment all appear to influence psychedelic experiences and outcomes, yet these dimensions are extremely difficult to replicate within laboratory animal models.

  • Cultural Context Matters

    In some Indigenous and traditional cultures, psychoactive plants and fungi have historically existed within communal, ceremonial and healing practices including within maternal life.

    For some women, awareness of these traditions has offered reassurance that psychedelics and motherhood are not inherently incompatible.

    At the same time, these practices exist within very different cultural, spiritual and communal frameworks than those found in modern Western societies. Indigenous traditions should not be simplified into direct evidence of safety within contemporary motherhood.

    Many people in the modern West are now attempting to rebuild relationship with these medicines without intact lineages, communal structures or intergenerational guidance, a process that requires humility, care and discernment.

    Honouring Indigenous traditions remains deeply important, particularly acknowledging the role of Indigenous healers such as María Sabina in preserving sacred mushroom knowledge despite exploitation and harm.

  • Maternal Wellbeing Matters Too

    Conversations around breastfeeding understandably tend to focus primarily on the infant. Questions around substances entering breastmilk are important and deserve careful consideration.

    But maternal wellbeing matters too.

    Postpartum life can place enormous demands on a woman’s nervous system, identity, relationships and emotional capacity. Many mothers find themselves navigating exhaustion, anxiety, depletion, overwhelm and isolation while simultaneously carrying cultural pressure to appear endlessly calm, grateful and self sacrificing.

    Within this context, some mothers describe microdosing as helping them feel:

    ● Less reactive,

    ● More emotionally present,

    ● More connected to themselves and their children,

    ● And more able to access calm, creativity or self-compassion.

    Others report no benefit at all, or find that microdosing increases emotional sensitivity or anxiety.

    Psychedelics are not inherently healing in every context, and microdosing is not a universal solution for the realities of motherhood. Experiences appear to be shaped by many factors including dosage, nervous system state, support systems, environment, intention and wider life circumstances.


  • Beyond “Safe” or “Unsafe”

    One limitation of modern conversations around risk is that they often seek absolute certainty where none exists.

    In reality, postpartum decision making is rarely black and white. Mothers make complex decisions every day around medication, sleep, nutrition, stress, work and caregiving often while balancing competing needs with incomplete information.

    For some women, the question is not whether there is zero risk, but how to navigate uncertainty consciously, responsibly and with care.

    This does not mean dismissing caution. It means recognising that lived decision-making is often more complex than simplistic binaries allow.

    Projects like Mothers of the Mushroom highlight the importance of creating more open, relational and non stigmatised conversations around psychedelics and motherhood, conversations grounded not in certainty or ideology, but in honesty, humility and care.

  • Final Thoughts

    Microdosing during breastfeeding sits within an area of significant uncertainty. There is currently insufficient research to make definitive safety claims, and caution is warranted.

    At the same time, reducing these conversations to simplistic narratives can overlook the wider realities of maternal mental health, nervous system wellbeing and the complexity of postpartum life.

    For mothers exploring these questions, informed decision making involves not only considering potential physiological risks, but also recognising the broader emotional, relational and cultural context in which these choices are being made.


  • About the Author

    Naomi Tolson is an MSc student in Psychedelics: Mind, Medicine and Culture at the University of Exeter, a trauma informed somatic counsellor, microdosing guide, founder of The Psychedelic Doula, and mother to three children.

    With a background in paediatric nursing, student midwifery and many years working as a birth keeper and doula, Naomi’s work sits at the intersection of motherhood, nervous system healing, relational care and psychedelic integration.

    She offers one to one support, workshops, courses and educational spaces exploring microdosing, motherhood, somatic healing and psychedelic integration through a grounded and non pathologising lens.

    For mothers navigating the complexity of microdosing, breastfeeding, pregnancy or the wider motherhood journey, having someone to walk beside you without judgement or agenda, can sometimes feel invaluable.

Related Products

CONTINUE READING